6 completed, 3 terminated, 2 not yet recruiting, 2 recruiting. 17 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 17 | Completed 6, Terminated 3, Not yet recruiting 2, Recruiting 2, Unknown 2, Active not recruiting 1, Enrolling by invitation 1 |
Follow Non-Small-Cell Lung Cancer: new trials by email Literature Review of Non-Small-Cell Lung Cancer trials Research Report on Non-Small-Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reduced-Dose vs Standard-Dose Thoracic Radiotherapy After Induction Chemoimmunotherapy in Older or Frail Stage III NSCLC Reduced-Dose Thoracic Radiotherapy, Standard-Dose Thoracic Radiotherapy - Non-Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | Ruijin Hospital | 276 | 2026-10-30 | 2026-11-02 |
| Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations Firmonertinib, EGFR-TKI inhibitor based on investigator's choice - Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Recruiting | ArriVent BioPharma, Inc. | 480 | 2025-12-17 | 2026-11-02 |
| Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure Vebreltinib, PLB1004, Pemetrexed plus Carboplatin or Cisplatin - Non-Small-Cell Lung Cancer | Phase 3 | Not yet recruiting | Avistone Biotechnology Co., Ltd. | 278 | 2025-05-15 | 2025-05-21 |
| Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. PLB1004, Pemetrexed+（carboplatin or Cisplatin）with or without Sintilimab - Non-Small-Cell Lung Cancer | Phase 3 | Enrolling by invitation | Avistone Biotechnology Co., Ltd. | 327 | 2023-12-01 | 2026-04-23 |
| Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC Camrelizumab, Placebo, Cisplatin - Non-Small-Cell Lung Cancer | Phase 3 | Completed | Guangdong Association of Clinical Trials | 60 | 2021-05-28 | 2026-05-20 |
| PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % Pembrolizumab, Pembrolizumab and Chemotherapy drugs - Non-small-cell Lung Cancer | Phase 3 | Active not recruiting | University Hospital, Brest | 349 | 2020-12-22 | 2025-09-17 |
| A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC SHR-1316、Paclitaxel (Albumin Bound)、Carboplatin, SHR-1316、Chemotherapeutic, Placebo、Chemotherapeutic - Non-Small-Cell Lung Cancer | Phase 3 | Recruiting | Jiangsu HengRui Medicine Co., Ltd. | 537 | 2020-07-14 | 2021-11-04 |
| 18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect of Chemotherapy Multicenter Clinical Study 18F-FDG - Non-small-cell Lung Cancer | Phase 3 | Unknown | Shanghai Chest Hospital | 200 | 2016-11-01 | 2016-10-21 |
| EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism EGFR-TKI, Chemotherapy（pemetrexed/gemcitabine）, Chemotherapy（carboplatin） - Non-Small-Cell Lung Cancer | Phase 3 | Unknown | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2016-08-01 | 2016-08-09 |
| Phase Ⅲ Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as first-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study Erlotinib, WBRT - Multiple Brain Metastases, Non-small-cell Lung Cancer | Phase 3 | Completed | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 224 | 2013-08-01 | 2016-08-25 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib ARQ 197 and Erlotinib, Placebo and Erlotinib - Non-small-cell Lung Cancer | Phase 3 | Terminated | Kyowa Kirin Co., Ltd. | 2011-07-01 | 2016-12-07 | |
| Randomized Customized Adjuvant Chemotherapy (GECP-SCAT) Docetaxel/Cisplatin control, Docetaxel, Gemcitabine/Cisplatin - Non-small-cell Lung Cancer | Phase 3 | Completed | Spanish Lung Cancer Group | 500 | 2007-06-01 | 2024-12-12 |
| Randomized Trial of Docetaxel and Gemcitabine Versus Gemcitabine in Elderly Patients With NSCLC Docetaxel, Gemcitabine - Non-small-cell Lung Cancer | Phase 3 | Terminated | Hellenic Oncology Research Group | 106 | 2006-12-01 | 2012-06-27 |
| A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC) Zoledronic acid 4 mg - Non-Small-Cell Lung Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 437 | 2005-03-01 | 2015-05-04 |
| Elderly NSCLC/D vs DP (JCOG0207) Weekly docetaxel alone, Weekly docetaxel + cisplatin combination - Non-small-cell Lung Cancer | Phase 3 | Terminated | Japan Clinical Oncology Group | 230 | 2003-04-01 | 2016-09-12 |
| Oral Topotecan Versus Intravenous Docetaxel In Pretreated, Advanced Non-Small Cell Lung Cancer topotecan - Non-Small-Cell Lung Cancer | Phase 3 | Completed | GlaxoSmithKline | 760 | 2001-10-01 | 2013-03-04 |
| Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer Neoadjuvant chemotherapy (taxol and carboplatin), Adjuvant chemotherapy (taxol and carboplatin), Surgery - Non-Small-Cell Lung Cancer | Phase 3 | Completed | Spanish Lung Cancer Group | 624 | 1999-09-01 | 2022-06-13 |
Carcinoma, Non-Small-Cell Lung (17) · Lung Neoplasms (3) · Bronchial Neoplasms (1) · Neoplasms (1) · Respiratory Tract Neoplasms (1)
Carcinoma, Bronchogenic (17) · Lung Diseases (17) · Neoplasms by Site (17) · Respiratory Tract Diseases (17) · Thoracic Neoplasms (17) · Bronchial Neoplasms (16) · Neoplasms (16) · Respiratory Tract Neoplasms (16) · Lung Neoplasms (14) · Bronchial Diseases (1)
Carboplatin (4) · Cisplatin (3) · Gemcitabine (3) · Pemetrexed (3) · Docetaxel (2) · Erlotinib Hydrochloride (2) · Paclitaxel (2) · 130-nm albumin-bound paclitaxel (1) · ARQ 197 (1) · Chemotherapy, Adjuvant (1) · Fluorodeoxyglucose F18 (1) · Gefitinib (1) · Neoadjuvant Therapy (1) · Surgical Procedures, Operative (1) · Topotecan (1)
Avistone Biotechnology Co., Ltd. (2) · Spanish Lung Cancer Group (2) · ArriVent BioPharma, Inc. (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · GlaxoSmithKline (1) · Guangdong Association of Clinical Trials (1) · Hellenic Oncology Research Group (1) · Japan Clinical Oncology Group (1) · Jiangsu HengRui Medicine Co., Ltd. (1) · Kyowa Kirin Co., Ltd. (1) · Novartis Pharmaceuticals (1) · Ruijin Hospital (1) · Shanghai Chest Hospital (1) · Shanghai Pulmonary Hospital, Shanghai, China (1) · University Hospital, Brest (1)
China (7) · France (4) · Greece (4) · Spain (4) · Italy (3) · Japan (3) · Taiwan (3) · Thailand (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Canada (2) · Germany (2) · Hungary (2) · Netherlands (2)
Akira Yokoyama, MD, PhD (1) · Athanasios Karampeazis, MD (1) · Caicun Zhou, MD, PHD (1) · Enriqueta Felip, MD (1) · Jamuna Thimmarayappa (1) · Jose Miguel Sanchez Torres, MD (1) · Lampros Vamvakas, MD (1) · Rafael Rosell, MD (1) · Wenhui Xie, PHD (1)
PMID 19487962, PMID 20516435, PMID 21617977, PMID 22326218, PMID 22730101, PMID 25378648, PMID 25783515, PMID 26153496, PMID 26703796, PMID 27153497, PMID 27236466, PMID 27264267, PMID 27607176, PMID 27659017, PMID 27683031, PMID 27690345, PMID 27710970, PMID 27729297, PMID 33331923, PMID 34156285, PMID 39830774, PMID 39929333